Methods to bypass CD4+ cells in the induction of an immune response
US8703142B2 · kind B2 · utility
15Cited by
8References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2005 |
| Grant date | Apr 22, 2014 |
| Priority date | — |
| Expiry date | Oct 19, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.